Physician profile
Frederick R Freeman
NPI 1720054646
$3,899.58
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.09 · 2020: $55.73 · 2021: $62.05 · 2022: $49.21 · 2023: $3,005 · 2024: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,925 · Travel and Lodging: $463 · Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,925.00 |
| Travel and Lodging | $462.51 |
| Food and Beverage | $278.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microline Surgical INC | $2,925.00 | 2023 | |
| Stryker Corporation | $625.54 | 2024 | Scopis Ent, Xpress Loprofile |
| Glaxosmithkline, LLC. | $50.87 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $48.77 | 2023-2024 | Farxiga |
| Amgen INC. | $38.71 | 2019-2020 | |
| Novo Nordisk INC | $29.55 | 2021 | |
| Abbvie INC. | $24.73 | 2022 | |
| Abbott Laboratories | $24.48 | 2022 | |
| Merck Sharp & Dohme LLC | $22.74 | 2019-2020 | |
| Lundbeck LLC | $18.27 | 2023 | Rexulti |
| Optinose US, INC. | $17.19 | 2021 | |
| Olympus America INC. | $15.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.31 | 2020 | |
| Amarin Pharma, INC. | $15.19 | 2020 | |
| Lilly USA, LLC | $14.68 | 2023 | Mounjaro |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.